ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved...

|About: NewLink Genetics Corporation (NLNK)|By:, SA News Editor

ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved survival rates in a Phase II trial of the company's algenpantucel-L treatment for pancreatic cancer. NewLink Genetics has also disclosed positive results in early stage trials of two other drugs (I, II).